1598 related articles for article (PubMed ID: 27412889)
1. T cells expressing an anti-B-cell maturation antigen chimeric antigen receptor cause remissions of multiple myeloma.
Ali SA; Shi V; Maric I; Wang M; Stroncek DF; Rose JJ; Brudno JN; Stetler-Stevenson M; Feldman SA; Hansen BG; Fellowes VS; Hakim FT; Gress RE; Kochenderfer JN
Blood; 2016 Sep; 128(13):1688-700. PubMed ID: 27412889
[TBL] [Abstract][Full Text] [Related]
2. T Cells Genetically Modified to Express an Anti-B-Cell Maturation Antigen Chimeric Antigen Receptor Cause Remissions of Poor-Prognosis Relapsed Multiple Myeloma.
Brudno JN; Maric I; Hartman SD; Rose JJ; Wang M; Lam N; Stetler-Stevenson M; Salem D; Yuan C; Pavletic S; Kanakry JA; Ali SA; Mikkilineni L; Feldman SA; Stroncek DF; Hansen BG; Lawrence J; Patel R; Hakim F; Gress RE; Kochenderfer JN
J Clin Oncol; 2018 Aug; 36(22):2267-2280. PubMed ID: 29812997
[TBL] [Abstract][Full Text] [Related]
3. B-cell maturation antigen is a promising target for adoptive T-cell therapy of multiple myeloma.
Carpenter RO; Evbuomwan MO; Pittaluga S; Rose JJ; Raffeld M; Yang S; Gress RE; Hakim FT; Kochenderfer JN
Clin Cancer Res; 2013 Apr; 19(8):2048-60. PubMed ID: 23344265
[TBL] [Abstract][Full Text] [Related]
4. The BCMA-Targeted Fourth-Generation CAR-T Cells Secreting IL-7 and CCL19 for Therapy of Refractory/Recurrent Multiple Myeloma.
Duan D; Wang K; Wei C; Feng D; Liu Y; He Q; Xu X; Wang C; Zhao S; Lv L; Long J; Lin D; Zhao A; Fang B; Jiang J; Tang S; Gao J
Front Immunol; 2021; 12():609421. PubMed ID: 33767695
[TBL] [Abstract][Full Text] [Related]
5. A bispecific CAR-T cell therapy targeting BCMA and CD38 in relapsed or refractory multiple myeloma.
Mei H; Li C; Jiang H; Zhao X; Huang Z; Jin D; Guo T; Kou H; Liu L; Tang L; Yin P; Wang Z; Ai L; Ke S; Xia Y; Deng J; Chen L; Cai L; Sun C; Xia L; Hua G; Hu Y
J Hematol Oncol; 2021 Oct; 14(1):161. PubMed ID: 34627333
[TBL] [Abstract][Full Text] [Related]
6. Therapeutic potential of third-generation chimeric antigen receptor T cells targeting B cell maturation antigen for treating multiple myeloma.
Rujirachaivej P; Siriboonpiputtana T; Luangwattananun P; Yuti P; Wutti-In Y; Choomee K; Sujjitjoon J; Chareonsirisuthigul T; Rerkamnuaychoke B; Junking M; Yenchitsomanus PT
Clin Exp Med; 2024 Apr; 24(1):90. PubMed ID: 38683232
[TBL] [Abstract][Full Text] [Related]
7. Long event-free survival after anti-BCMA CAR-T cell treatment for relapsed and refractory multiple myeloma patients: Two case reports.
Xu J; Ming X; Wang C; Xu B; Xiao Y
Medicine (Baltimore); 2021 May; 100(18):e25784. PubMed ID: 33950974
[TBL] [Abstract][Full Text] [Related]
8. Chimeric antigen receptor T cell targeting B cell maturation antigen immunotherapy is promising for multiple myeloma.
Ma T; Shi J; Liu H
Ann Hematol; 2019 Apr; 98(4):813-822. PubMed ID: 30693373
[TBL] [Abstract][Full Text] [Related]
9. A phase 1 study of a novel fully human BCMA-targeting CAR (CT103A) in patients with relapsed/refractory multiple myeloma.
Wang D; Wang J; Hu G; Wang W; Xiao Y; Cai H; Jiang L; Meng L; Yang Y; Zhou X; Hong Z; Yao Z; Xiao M; Chen L; Mao X; Zhu L; Wang J; Qiu L; Li C; Zhou J
Blood; 2021 May; 137(21):2890-2901. PubMed ID: 33512480
[TBL] [Abstract][Full Text] [Related]
10. Effective Targeting of Multiple B-Cell Maturation Antigen-Expressing Hematological Malignances by Anti-B-Cell Maturation Antigen Chimeric Antigen Receptor T Cells.
Friedman KM; Garrett TE; Evans JW; Horton HM; Latimer HJ; Seidel SL; Horvath CJ; Morgan RA
Hum Gene Ther; 2018 May; 29(5):585-601. PubMed ID: 29641319
[TBL] [Abstract][Full Text] [Related]
11. B cell maturation antigen-specific chimeric antigen receptor T cells for relapsed or refractory multiple myeloma: A meta-analysis.
Gagelmann N; Ayuk F; Atanackovic D; Kröger N
Eur J Haematol; 2020 Apr; 104(4):318-327. PubMed ID: 31883150
[TBL] [Abstract][Full Text] [Related]
12. Efficacy of Humanized Anti-BCMA CAR T Cell Therapy in Relapsed/Refractory Multiple Myeloma Patients With and Without Extramedullary Disease.
Deng H; Liu M; Yuan T; Zhang H; Cui R; Li J; Yuan J; Wang X; Wang Y; Deng Q
Front Immunol; 2021; 12():720571. PubMed ID: 34421924
[TBL] [Abstract][Full Text] [Related]
13. A phase I study of anti-BCMA CAR T cell therapy in relapsed/refractory multiple myeloma and plasma cell leukemia.
Li C; Cao W; Que Y; Wang Q; Xiao Y; Gu C; Wang D; Wang J; Jiang L; Xu H; Xu J; Zhou X; Hong Z; Wang N; Huang L; Zhang S; Chen L; Mao X; Xiao M; Zhang W; Meng L; Cao Y; Zhang T; Li J; Zhou J
Clin Transl Med; 2021 Mar; 11(3):e346. PubMed ID: 33784005
[TBL] [Abstract][Full Text] [Related]
14. Overview of anti-BCMA CAR-T immunotherapy for multiple myeloma and relapsed/refractory multiple myeloma.
Feng D; Sun J
Scand J Immunol; 2020 Aug; 92(2):e12910. PubMed ID: 32471019
[TBL] [Abstract][Full Text] [Related]
15. Preclinical Evaluation of Allogeneic CAR T Cells Targeting BCMA for the Treatment of Multiple Myeloma.
Sommer C; Boldajipour B; Kuo TC; Bentley T; Sutton J; Chen A; Geng T; Dong H; Galetto R; Valton J; Pertel T; Juillerat A; Gariboldi A; Pascua E; Brown C; Chin SM; Sai T; Ni Y; Duchateau P; Smith J; Rajpal A; Van Blarcom T; Chaparro-Riggers J; Sasu BJ
Mol Ther; 2019 Jun; 27(6):1126-1138. PubMed ID: 31005597
[TBL] [Abstract][Full Text] [Related]
16. [CAR-T cells immunotherapy in multiple myeloma: Present and future].
Ferment B; Arnulf B
Bull Cancer; 2021 Oct; 108(10S):S65-S72. PubMed ID: 34920809
[TBL] [Abstract][Full Text] [Related]
17. B cell maturation antigen-specific CAR T cells are clinically active in multiple myeloma.
Cohen AD; Garfall AL; Stadtmauer EA; Melenhorst JJ; Lacey SF; Lancaster E; Vogl DT; Weiss BM; Dengel K; Nelson A; Plesa G; Chen F; Davis MM; Hwang WT; Young RM; Brogdon JL; Isaacs R; Pruteanu-Malinici I; Siegel DL; Levine BL; June CH; Milone MC
J Clin Invest; 2019 Mar; 129(6):2210-2221. PubMed ID: 30896447
[TBL] [Abstract][Full Text] [Related]
18. γ-Secretase inhibitor in combination with BCMA chimeric antigen receptor T-cell immunotherapy for individuals with relapsed or refractory multiple myeloma: a phase 1, first-in-human trial.
Cowan AJ; Pont MJ; Sather BD; Turtle CJ; Till BG; Libby EN; Coffey DG; Tuazon SA; Wood B; Gooley T; Wu VQ; Voutsinas J; Song X; Shadman M; Gauthier J; Chapuis AG; Milano F; Maloney DG; Riddell SR; Green DJ
Lancet Oncol; 2023 Jul; 24(7):811-822. PubMed ID: 37414012
[TBL] [Abstract][Full Text] [Related]
19. BCMA-Targeted CAR T-cell Therapy plus Radiotherapy for the Treatment of Refractory Myeloma Reveals Potential Synergy.
Smith EL; Mailankody S; Staehr M; Wang X; Senechal B; Purdon TJ; Daniyan AF; Geyer MB; Goldberg AD; Mead E; Santomasso BD; Landa J; Rimner A; Riviere I; Landgren O; Brentjens RJ
Cancer Immunol Res; 2019 Jul; 7(7):1047-1053. PubMed ID: 31113804
[TBL] [Abstract][Full Text] [Related]
20. Targeting B Cell Maturation Antigen (BCMA) in Multiple Myeloma: Potential Uses of BCMA-Based Immunotherapy.
Cho SF; Anderson KC; Tai YT
Front Immunol; 2018; 9():1821. PubMed ID: 30147690
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
